Intracutaneous and Intravesical Immunotherapy With Keyhole Limpet Hemocyanin Compared With Intravesical Mitomycin in Patients With Non-Muscle-Invasive Bladder Cancer: Results From a Prospective Randomized Phase III Trial.

Lammers RJ, Witjes WP, Janzing-Pastors MH, Caris CT, Witjes JA

J Clin Oncol. 2012 May 14

Hemocyanins as immunostimulants

Del Campo M, Arancibia S, Nova E, Salazar F, González A, Moltedo B, De Ioannis P, Ferreira J, Manubens A, Becker MI.

Rev Med Chil. 2011 Feb;139(2):236-46. Epub 2011 Jul 11

Evaluation of human antibody responses to keyhole limpet hemocyanin on a carbohydrate microarray

Oyelaran O, Gildersleeve JC.

Proteomics Clin Appl. 2010 Mar;4(3):285-94. doi: 10.1002/prca.200900130. Epub 2010 Feb 11

Superficial bladder cancer therapy

Emmanuel Schenkman, M.D. and Donald L. Lamm, M.D.

ScientificWorldJ (2004) 4 (S1), 387–399

Laboratory and clinical experience with keyhole limpet hemocyanin (Immucothel(r)) in superficial bladder cancer

Lamm.

J Urol Urogynäkol (Österreich) 2003; 10 (2): 18–21

Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study

Jurincic-Winkler CD, Metz KA, Beuth J, Klippel KF.

Eur Urol. 2000;37 Suppl 3:45-9

Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies

Lamm DL, Dehaven JI, Riggs DR.

Eur Urol. 2000;37 Suppl 3:41-4

Efficacy of prophylactic Immucothel in patients pretreated with conventional drugs to prevent recurrence of superficial bladder carcinoma

Echarti C, Jurincic-Winkler CD, Klippel KF.

Eur Urol. 2000;37 Suppl 3:50-3

Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results

Linn JF, Black P, Derksen K, Rübben H, Thüroff JW

Eur Urol. 2000;37 Suppl 3:34-40

Immunotherapy of bladder cancer

Nseyo UO, Lamm DL.

Semin Surg Oncol. 1997 Sep-Oct; 13(5):342-9